Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's ...

On the company’s earnings call yesterday, Chief Scientific Officer Dan Skrovronsky said it plans to start a Phase 3 trial of its GLP-1 pill, orforglipron, in hypertension. Lilly also plans to ...

and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new prescriptions bodes well for similar 2025 gains. The bottom ...

Can Lilly immunize retatrutide from compounded copies? Will the district court second guess – much less overturn – FDA’s decision to regulate this GLP-1 as a drug? Although perhaps a bit ...

NVO’s arch-rival, Lilly, markets tirzepatide, a dual GIP and GLP-1 receptor agonist, as Mounjaro for T2D and Zepbound for obesity. In the past three months, shares of Novo Nordisk and Lilly have ...

Holz also highlights that Eli Lilly's pipeline, especially in GLP-1 treatments, remains promising for long-term growth. "The GLP-1 class is the most important category by far, and they're going to ...